Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies |
| |
| Affiliation: | 1. Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York;2. Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen;3. Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC;4. Probity Medical Research and K. Papp Clinical Research, Waterloo;5. Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago;6. Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel;7. Department of Dermatology and Skin Science, University of British Columbia, Vancouver, and Probity Medical Research, Surrey;8. AbbVie Inc, North Chicago;9. Clinical Medicine, Trinity College, Dublin, and Wellcome Trust-HRB Clinical Research Facility, St James’ Hospital, Dublin |
| |
| Abstract: | |
| |
| Keywords: | Atopic dermatitis Janus kinase inhibitor safety upadacitinib AD" },{" #name" :" keyword" ," $" :{" id" :" kwrd0035" }," $$" :[{" #name" :" text" ," _" :" Atopic dermatitis AE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0045" }," $$" :[{" #name" :" text" ," _" :" Adverse event AESI" },{" #name" :" keyword" ," $" :{" id" :" kwrd0055" }," $$" :[{" #name" :" text" ," _" :" AEs of special interest ALT" },{" #name" :" keyword" ," $" :{" id" :" kwrd0065" }," $$" :[{" #name" :" text" ," _" :" Alanine aminotransferase AST" },{" #name" :" keyword" ," $" :{" id" :" kwrd0075" }," $$" :[{" #name" :" text" ," _" :" Aspartate aminotransferase CI" },{" #name" :" keyword" ," $" :{" id" :" kwrd0085" }," $$" :[{" #name" :" text" ," _" :" Confidence interval CPK" },{" #name" :" keyword" ," $" :{" id" :" kwrd0095" }," $$" :[{" #name" :" text" ," _" :" Creatine phosphokinase E/100 PY" },{" #name" :" keyword" ," $" :{" id" :" kwrd0105" }," $$" :[{" #name" :" text" ," _" :" Events per 100 PY EAER" },{" #name" :" keyword" ," $" :{" id" :" kwrd0115" }," $$" :[{" #name" :" text" ," _" :" Exposure-adjusted event rate EAIR" },{" #name" :" keyword" ," $" :{" id" :" kwrd0125" }," $$" :[{" #name" :" text" ," _" :" Exposure-adjusted incidence rate EH" },{" #name" :" keyword" ," $" :{" id" :" kwrd0135" }," $$" :[{" #name" :" text" ," _" :" Eczema herpeticum HZ" },{" #name" :" keyword" ," $" :{" id" :" kwrd0145" }," $$" :[{" #name" :" text" ," _" :" Herpes zoster JAK" },{" #name" :" keyword" ," $" :{" id" :" kwrd0155" }," $$" :[{" #name" :" text" ," _" :" Janus kinase MACE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0165" }," $$" :[{" #name" :" text" ," _" :" Major adverse cardiovascular events MedDRA" },{" #name" :" keyword" ," $" :{" id" :" kwrd0175" }," $$" :[{" #name" :" text" ," _" :" Medical Dictionary for Regulatory Activities NMSC" },{" #name" :" keyword" ," $" :{" id" :" kwrd0185" }," $$" :[{" #name" :" text" ," _" :" Nonmelanoma skin cancer PY" },{" #name" :" keyword" ," $" :{" id" :" kwrd0195" }," $$" :[{" #name" :" text" ," _" :" Patient-years RA" },{" #name" :" keyword" ," $" :{" id" :" kwrd0205" }," $$" :[{" #name" :" text" ," _" :" Rheumatoid arthritis SAE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0215" }," $$" :[{" #name" :" text" ," _" :" Serious AE SIR" },{" #name" :" keyword" ," $" :{" id" :" kwrd0225" }," $$" :[{" #name" :" text" ," _" :" Standardized incidence ratio TB" },{" #name" :" keyword" ," $" :{" id" :" kwrd0235" }," $$" :[{" #name" :" text" ," _" :" Tuberculosis TEAE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0245" }," $$" :[{" #name" :" text" ," _" :" Treatment-emergent AEs VTE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0255" }," $$" :[{" #name" :" text" ," _" :" Venous thromboembolism |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
